TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20110017
Drug: Glimepiride 1-mg
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1-mg + Metformin 500-mg combination tablet (test)
Study: 20110017
Drug: Glimepiride 2-mg
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2-mg + Metformin 500-mg combination tablet (reference)
Study: 16882276
Drug: Pioglitazone (30-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30-45 mg daily for 26 weeks)
Study: 3046984
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of pectin
Study: 3046984
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of pectin
Study: 3046984
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of pectin
Study: 29505900
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) plus Carboplatin (AUC 5) every 3 weeks for four cycles (arm A)
Study: 29505900
Drug: Oral Uracil-Tegafur
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Uracil-Tegafur (UFT) (250 mg/m2) daily for 2 years (arm B)
Study: 22657157
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/m(2)/wk and prednisone 1 mg/kg/d (maximum 50 mg) for the first 3 months
Study: 20491606
Drug: Candesartan-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan-based treatment
Study: 29734096
Drug: Antidepressants (bupropion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (bupropion, paroxetine) as adjuncts to mood stabilizers
Study: 29734096
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as adjunct to mood stabilizers
Study: 25199409
Drug: Diminazene diaceturate
Normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diminazene diaceturate (DA) treatment
Study: 24319686
Drug: Nilvadipine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (oral administration)
Study: 20958228
Drug: L-arginine (L-Arg)
Normalized name: L-Arg
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (L-Arg) supplementation
Study: 18509120
Drug: Subcutaneous methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous methylnaltrexone (0.15 mg/kg)
Study: 11232191
Drug: Specific vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific vaccines for hepatitis A and B
Study: 11232191
Drug: Aggressive combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive combination therapy for chronic hepatitis B and C
Study: 9081951
Drug: 0.4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml/kg (1:200,000) epinephrine combined with 0.25% bupivacaine (n = 33)
Study: 1313098
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg orally four times daily for 5 days)
Study: 2860992
Drug: Atenolol (Tenormin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (Tenormin, 100 mg) given twice daily for 6 weeks
Study: 30848938
Drug: 4-week multimodal
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week multimodal rehabilitation program (12 intervention sessions and daily home ankle strengthening and stretching)
Study: 29547070
Drug: Combination HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV prevention intervention
Study: 26845264
Drug: Lithium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium + adjunctive personalized treatment (APT)
Study: 26845264
Drug: Quetiapine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine + adjunctive personalized treatment (APT)
Study: 22818869
Drug: Vitamin B(6)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(6) (50 mg/d)
Study: 22818869
Drug: Lysine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine (1 g/d)
Study: 22818869
Drug: Carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine (1 g/d)
Study: 22818869
Drug: Lysine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine (1 g/d) + Vitamin B(6) (50 mg/d)
Study: 20631020
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (150,000 IU ergocalciferol, 4 doses over 1 year)
Study: 12574809
Drug: Melagatran followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melagatran followed by oral ximelagatran (3 mg subcutaneous melagatran started 4-12 h postoperatively, followed by 24 mg oral ximelagatran twice-daily for 8 to 11 days)
Study: 12574809
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg subcutaneous enoxaparin once-daily, started 12 h preoperatively)
Study: 1587940
Drug: 1% solution
Normalized name: GUMSOL 5%-0.01% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% solution of povidon iodine (Betadine)
Study: 3907910
Drug: Verapamil 20
Normalized name: verapamil 200 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 20 mg intravenously
Study: 30773140
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplement with additional micronutrients
Study: 30773140
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplement without additional micronutrients
Study: 20003665
Drug: Cranberry drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry drink (500 ml twice per day)
Study: 8769051
Drug: GR3219 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR3219 80 mg twice daily
Study: 1573046
Drug: Alprazolam 6
Normalized name: Acetylcarnitine/Choline Bitartrate/Cocoa Extract/Gamma Aminobutyric Acid/Ginkgo Biloba Leaf/Glutamic Acid/Grape Seed Extract/Griffonia Seed Extract/Valerian Root Extract/Whey Protein Hydrolysate;Alprazolam 62.5 MG; 0.5 MG Oral Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 6 mg
Study: 3881905
Drug: Nifedipine in
Normalized name: nifedipine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine in cold hyperkalemic cardioplegic solution
Study: 29368365
Drug: Phlorotannin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlorotannin supplement (500 mg/day)
Study: 26850983
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 μg every 4 hours)
Study: 26850983
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter (30 mL transcervical)
Study: 24550378
Drug: Caspofungin preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin preemptive therapy
Study: 24550378
Drug: Placebo preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preemptive therapy
Study: 22099607
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (escitalopram)
Study: 20819537
Drug: Nifekalant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Nifekalant (DB16008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifekalant hydrochloride (NIF) administered continuously for at least 12 hours (group L)
Study: 20819537
Drug: Nifekalant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Nifekalant (DB16008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifekalant hydrochloride (NIF) administered for 1 hour (group S)
Study: 16409566
Drug: Irbesartan, 300
Normalized name: Irbesartan, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan, 300 mg
Study: 14978984
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg (intravenous) 8 hourly
Study: 14978984
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g 8 hourly through a Ryle's tube
Study: 28520861
Drug: Post-coronary artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-coronary artery bypass grafting medication - Acetylsalicylic acid
Study: 28520861
Drug: Post-coronary artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-coronary artery bypass grafting medication - Thienopyridine
Study: 28520861
Drug: Post-coronary artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-coronary artery bypass grafting medication - Statins
Study: 21301783
Drug: 5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg/kg methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim)
Study: 21226428
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg (1.5 ml) hyperbaric levobupivacaine 0.5%
Study: 21226428
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg (4 ml) hypobaric levobupivacaine 0.1875%
Study: 9481529
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Study: 9481529
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Study: 8570043
Drug: Iodixanol 150
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol 150 mgI/ml
Study: 8570043
Drug: Iohexol 140
Normalized name: iohexol 140 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 140 mgI/ml
Study: 2096212
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg orally twice daily for 3.5 days
Study: 81925
Drug: Propranolol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.1 mg/kg intravenously followed by 320 mg orally over 27 h
Study: 31940039
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA level of 0.49 ng/mL or less
Study: 31940039
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA level of 0.50-0.99 ng/mL
Study: 31940039
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA level of 1.00-1.99 ng/mL
Study: 31940039
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA level of 2.00-2.99 ng/mL
Study: 31940039
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA level of 3.00-3.99 ng/mL
Study: 31940039
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA level of 4.00 ng/mL and greater
Study: 31940039
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA level of 2.00 ng/mL or higher
Study: 28434547
Drug: Stress-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress-dose corticosteroid (SDC) regimen: 2 mg/kg methylprednisolone perioperatively, followed by hydrocortisone infusion (0.2 mg/kg/h) for 5 days
Study: 25585082
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical diltiazem ointment (for 6 weeks) and botulinum toxin A injection (once)
Study: 23507282
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg solithromycin orally on day 1, followed by 400 mg orally daily on days 2 to 5
Study: 23507282
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg levofloxacin orally daily on days 1 to 5
Study: 19452377
Drug: SSRIs (citalopram,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)
Study: 11146900
Drug: Propinox 10
Normalized name: propinox 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propinox 10 mg
Study: 11146900
Drug: Propinox 20
Normalized name: propinox 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propinox 20 mg
Study: 11146900
Drug: Propinox 30
Normalized name: propinox 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propinox 30 mg
Study: 3518408
Drug: 5-Aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-Aminosalicylic acid (5-ASA) enema (4-g nightly retention)
Study: 30242335
Drug: Canakinumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (50 mg, 150 mg, or 300 mg) administered subcutaneously every 3 months
Study: 23418746
Drug: 1-piece (STM)
Normalized name: STM 217
DrugBank: STM-217 (DB17358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-piece (STM) dental implant system
Study: 23418746
Drug: 2-piece (BRA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-piece (BRA) dental implant system
Study: 22592097
Drug: Fosamprenavir (FPV)
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosamprenavir (FPV) with or without ritonavir (100 mg or 200 mg)
Study: 12693575
Drug: Clue chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clue chemotherapy
Study: 12693575
Drug: Screen chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screen chemotherapy
Study: 10091208
Drug: OAC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole 20 mg/12 h, amoxycillin 1 g/12 h, clarithromycin 500 mg/12 h)
Study: 10091208
Drug: OCM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM (omeprazole 20 mg/12 h, clarithromycin 500 mg/12 h, metronidazole 500 mg/12 h)
Study: 10091208
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 30 mg/12 h, amoxycillin 1 g/12 h, clarithromycin 500 mg/12 h)
Study: 10091208
Drug: LC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC (lansoprazole 30 mg/12 h, clarithromycin 500 mg/8 h)
Study: 10091208
Drug: Overall triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall triple therapy
Study: 7502549
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (Salofalk, 4.5 g/day)
Study: 7502549
Drug: 6-methylprednisolone (Urbason,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methylprednisolone (Urbason, initial dose 48 mg/day, weekly tapering)
Study: 2258142
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with interferon antibodies
Study: 2258142
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without interferon antibodies
Study: 2258142
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with high titer neutralizing antibodies
Study: 7269436
Drug: Health resort
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health resort and sanatorium treatment
Study: 31243733
Drug: Vaccine (VAC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (VAC, fed with basal diet and injected with NDV vaccine)
Study: 31243733
Drug: Vaccine +
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine + Probiotic Bacillus cereus PAS38 (PBVAC)
Study: 16602471
Drug: Different antibiotics
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different antibiotics (specific types not mentioned)
Study: 11846850
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg, 1x daily for 3 days at week 2)
Study: 6831292
Drug: Midazolam (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.08 mg.kg‐1)
Study: 6831292
Drug: Hydroxyzine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (1.5 mg.kg‐1)
Study: 6831292
Drug: Hyoscine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine (0.4 mg)
Study: 6831292
Drug: Atropine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.4 mg)
Study: 31752978
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual treatment by GPs)
Study: 30044486
Drug: Naloxegol 25
Normalized name: naloxegol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 25 mg daily
Study: 30044486
Drug: Naloxegol 12.5
Normalized name: naloxegol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 12.5 mg daily
Study: 27007995
Drug: Single-dose zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose zonisamide at 200 mg
Study: 27007995
Drug: Single-dose zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose zonisamide at 300 mg
Study: 27007995
Drug: Single-dose zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose zonisamide at 400 mg
Study: 27007995
Drug: Multiple-dose zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Multiple-dose zonisamide at 300 mg for 14 days
Study: 21722193
Drug: Overdenture supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdenture supported by two implants with ball attachments (2IBA)
Study: 21722193
Drug: Overdenture supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdenture supported by four implants with a triple bar (4ITB)
Study: 21722193
Drug: Overdenture supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdenture supported by two implants with a bar (2ISB)
Study: 15786427
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (3 litres of polyethylene glycol)
Study: 15786427
Drug: Surgery without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery without mechanical bowel preparation
Study: 11963202
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors administered periprocedurally
Study: 8577008
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (24-hour combined infusion with fat, amino acids, and glucose)
Study: 8577008
Drug: Sequential infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential infusion (combined fat and amino acids during daytime and glucose alone during nighttime)
Study: 8577008
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion (nutrition provided by bolus infusions during 1 hour followed by 2 hours without any infusion)
Study: 1961129
Drug: Combined estrogen-progestogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen-progestogen therapy
Study: 6420178
Drug: Cyclosporine or
Normalized name: cyclosporine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine or methotrexate therapy
Study: 28528605
Drug: Calcipotriene/Betamethasone dipropionate
Normalized name: calcipotriene/betamethasone dipropionate 0.005 %-0.064 % TOPICAL FOAM (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene/Betamethasone dipropionate ointment
Study: 22763150
Drug: Leflunomide 100
Normalized name: leflunomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide 100 mg/week
Study: 22763150
Drug: Methotrexate 10
Normalized name: methotrexate 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 10 mg/week
Study: 11040240
Drug: High-dose adrenomedullin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenomedullin (5.8 pmol.kg(‐1).min(‐1))
Study: 11040240
Drug: Low-dose adrenomedullin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adrenomedullin (2.9 pmol.kg(‐1).min(‐1))
Study: 9569805
Drug: Local metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local metronidazole treatment
Study: 9569805
Drug: Systemic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic metronidazole treatment
Study: 8409183
Drug: dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: dobutamine infusion
Study: 31097858
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (standard protocol for 12 weeks, 3 sessions weekly for 60 minutes each)
Study: 19430625
Drug: Ice pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice pretreatment (cooling + topical anesthesia + counterstimulation + distraction)
Study: 19430625
Drug: Without ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without ice pretreatment (topical anesthesia + counterstimulation + distraction)
Study: 15498088
Drug: Glargine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glargine (once daily at dinner-time)
Study: 22933433
Drug: Medium fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium fructose (MF) at 40 g/day
Study: 22933433
Drug: High fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fructose (HF) at 80 g/day
Study: 22933433
Drug: High glucose
Normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glucose (HG) at 80 g/day
Study: 22933433
Drug: High sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High sucrose (HS) at 80 g/day
Study: 21909500
Drug: Semiannual topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiannual topical fluoride application (elmex fluid)
Study: 16507801
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 microg/kg subcutaneously daily for 5 days)
Study: 14725512
Drug: IM midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IM midazolam 0.04 mg.kg(‐1) (Group M1)